Search Results for: Boehringer
M&A Immuno-oncology
Sanofi Looks to Bolster Immunology Pipeline By Acquiring Kymab for $1.5 Billion
2021-01-13
M&A
Servier Aims to Expand Portfolio for Hematological Cancers by Acquiring Agios
2020-12-23
M&A iADC platform
Boehringer Ingelheim’s Newest Acquisition Reinforces its Focus on Immuno-Oncology
2020-12-14
Funding
Dewpoint Snags Successful Series B to Target Lesser Known Cellular Compartments
2020-10-02
R&D
Spotlight: The Many Facets of AstraZeneca’s Farxiga
2020-05-15
R&D Ras
AACR 2020: Targeting the KRAS Pathway – Old Protein, New Approaches
2020-04-30
Trials & Approvals Lung Cancer
Janssen Bags FDA Breakthrough Therapy Designation for Lung Cancer Drug
2020-03-12
Trials & Approvals Chronic Fibrosis
Boehringer Ingelheim’s Ofev Becomes First FDA Approved Treatment for Progressive Interstitial Lung Diseases
2020-03-11
R&D GalNAC
Novo Nordisk Becomes Dicerna’s Fifth Big Pharma Partnership
2019-11-19
R&D Anti-fibrotic
Boehringer Ingelheim’s New Drug – Nintedanib – Lowers Pulmonary Fibrosis by 57%
2019-10-21
sNDA
Weekly in Asia 2019｜JULY
2019-07-11
M&A Immune Design
Merck set to acquire Tilos Therapeutics for $773 million
2019-06-12
R&D
A new player emerges in the non-small cell lung cancer (NSCLC) therapy scene
2018-10-11
1 2 3
Newsletter

Subscribe to receive updates.

SIGN UP
Facebook
Youtube
Twitter
Linkedin
About
Explore
More
© 2024 GeneOnline
Privacy Policy | Terms of Service
Privacy Policy | Terms of Service
  • Subscribe to our newsletter and dive into the world of biopharma with us.
SIGN UP
x
Scroll to Top